




# CD86 Recombinant Protein

Cat. No.: 96-119




## Ψ Specifications

<b>SPECIES:</b>	Cynomolgus monkey
<b>SOURCE SPECIES:</b>	HEK293 cells
<b>SEQUENCE:</b>	Ala 19 - His 240
<b>FUSION TAG:</b>	C-Fc Tag
<b>TESTED APPLICATIONS:</b>	WB
<b>APPLICATIONS:</b>	This recombinant protein can be used for WB. For research use only.
<b>PREDICTED MOLECULAR WEIGHT:</b>	52 kDa

## Ψ Properties

<b>PURITY:</b>	95% as determined by SDS-PAGE.
<b>PHYSICAL STATE:</b>	Lyophilized
<b>BUFFER:</b>	Tris with Glycine, Arginine and NaCl, pH7.5
<b>STORAGE CONDITIONS:</b>	Lyophilized Protein should be stored at -20 °C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20 °C or -70 °C. Avoid repeated freeze-thaw cycles.

<b>OFFICIAL SYMBOL:</b>	CD86
<b>ALTERNATE NAMES:</b>	CD86, B7-2, B70, CD28LG2, LAB72, MGC34413
<b>ACCESSION NO.:</b>	Q9BDM4
<b>GENE ID:</b>	714390

 Background and References

<b>BACKGROUND:</b>	Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon $\gamma$ . CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF- $\kappa$ B-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.
<b>REFERENCES:</b>	1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
	2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
	3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.

**ANTIBODIES FOR RESEARCH USE ONLY.**

For additional information, visit ProSci's [Terms & Conditions Page](#).